Health & Fitness
Health and Fitness
Health and Fitness
Wed, November 11, 2009Tue, November 10, 2009Mon, November 9, 2009Fri, November 6, 2009Thu, November 5, 2009Wed, November 4, 2009Tue, November 3, 2009Mon, November 2, 2009Sun, November 1, 2009Fri, October 30, 2009Thu, October 29, 2009Wed, October 28, 2009Tue, October 27, 2009Mon, October 26, 2009Sun, October 25, 2009Fri, October 23, 2009Thu, October 22, 2009Wed, October 21, 2009Tue, October 20, 2009Mon, October 19, 2009Fri, October 16, 2009Thu, October 15, 2009Wed, October 14, 2009Tue, October 13, 2009Mon, October 12, 2009Fri, October 9, 2009Thu, October 8, 2009Wed, October 7, 2009Tue, October 6, 2009Mon, October 5, 2009Sun, October 4, 2009Fri, October 2, 2009Thu, October 1, 2009Wed, September 30, 2009Tue, September 29, 2009Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
Published in Health and Fitness on Friday, October 23rd 2009 at 9:24 GMT by Market Wire
A live audio link to the webcast presentation is available at:
[ http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ONC.TO&item_id=2478360 ] , or on the company's website at [ www.oncolyticsbiotech.com ]. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.
An audio replay will be accessible approximately one hour following the presentation on the Oncolytics website.
About BIO Investor Forum
BIO Investor Forum is a national investor forum to explore investment trends and opportunities in life sciences, with a focus on public and venture-stage growth companies as well as those poised to join the growth "watch list" in 2010.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN(R), its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: [ www.oncolyticsbiotech.com ].
The presentation and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
%SEDAR: 00013081E
